Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States.
Matthew MatasarJavier Sanchez AlvarezHelene PariseEric ZukDanilo Di MaioSheila ShapouriEunice KimShih-Wen LinPublished in: Journal of medical economics (2024)
Mosunetuzumab is estimated to be cost-effective compared with approved regimens except R-Len for the treatment of adults with R/R FL.